Sonoma Pharmaceuticals, Inc. (SNOA)
NASDAQ: SNOA · Real-Time Price · USD
1.100
-0.100 (-8.33%)
At close: Oct 30, 2026, 4:00 PM EDT
1.095
-0.005 (-0.45%)
After-hours: Oct 30, 2026, 7:30 PM EDT
Sonoma Pharmaceuticals Revenue
Sonoma Pharmaceuticals had revenue of $6.41M in the quarter ending June 30, 2026, with 59.55% growth. This brings the company's total for the last twelve months to $21.92M, up 47.00% year-over-year. In the fiscal year ending March 31, 2026, Sonoma Pharmaceuticals had annual revenue of $19.53M with 36.68% growth. That makes Sonoma Pharmaceuticals the 33,246th largest company in the world by revenue and 4,363rd in the United States.
Revenue (ttm)
$21.92M
Revenue Growth
+47.00%
P/S Ratio
0.24
Revenue / Employee
$2,192,000
Employees
10
Market Cap
5.27M
Revenue by Geography
- Europe 6.90M 35.4%
- United States 5.67M 29.1%
- Asia 2.90M 14.8%
- Latin America 2.37M 12.2%
- Rest of The World 1.68M 8.6%
Fiscal year ended Mar 31, 2026 See the full Sonoma Pharmaceuticals breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 19.53M | 5.24M | 36.68% |
| Mar 31, 2025 | 14.29M | 1.55M | 12.19% |
| Mar 31, 2024 | 12.74M | -537.00K | -4.05% |
| Mar 31, 2023 | 13.27M | 644.00K | 5.10% |
| Mar 31, 2022 | 12.63M | -6.00M | -32.21% |
| Mar 31, 2021 | 18.63M | 701.00K | 3.91% |
| Mar 31, 2020 | 17.93M | -1.04M | -5.49% |
| Mar 31, 2019 | 18.97M | 2.31M | 13.88% |
| Mar 31, 2018 | 16.66M | 3.83M | 29.89% |
| Mar 31, 2017 | 12.83M | 3.46M | 36.89% |
| Mar 31, 2016 | 9.37M | -4.49M | -32.37% |
| Mar 31, 2015 | 13.85M | 186.00K | 1.36% |
| Mar 31, 2014 | 13.67M | -1.78M | -11.55% |
| Mar 31, 2013 | 15.45M | 2.71M | 21.25% |
| Mar 31, 2012 | 12.74M | 2.99M | 30.65% |
| Mar 31, 2011 | 9.75M | 2.39M | 32.46% |
| Mar 31, 2010 | 7.36M | 1.98M | 36.67% |
| Mar 31, 2009 | 5.39M | 1.55M | 40.50% |
| Mar 31, 2008 | 3.84M | -708.00K | -15.58% |
| Mar 31, 2007 | 4.54M | 1.96M | 75.81% |
| Mar 31, 2006 | 2.58M | 1.23M | 90.56% |
| Mar 31, 2005 | 1.36M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Biofrontera | 46.18M |
| cbdMD | 20.93M |
| Universe Pharmaceuticals INC | 17.74M |
| InMed Pharmaceuticals | 4.94M |
| Akanda | 662.47K |
| Gelteq | 314.70K |
| RedHill Biopharma | 286.00K |
| Optimi Health | 123.70K |
SNOA News
- 2 months ago - Sonoma Pharmaceuticals reports Q1 EPS (9c) vs. (76c) last year - TheFly
- 2 months ago - Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA - Accesswire
- 4 months ago - Sonoma Pharmaceuticals receives 510(k) clearance for Microdacyn solution - TheFly
- 4 months ago - Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation Solution - Accesswire
- 4 months ago - Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results - Accesswire
- 6 months ago - Sonoma Pharmaceuticals prices 2.96M shares at $1.35 in public offering - TheFly
- 6 months ago - Sonoma Pharmaceuticals Announces Pricing of $4 Million Public Offering - Accesswire
- 6 months ago - Sonoma Pharmaceuticals files to sell units, no amount given - TheFly